Silicon Valley vaccine maker targets $100M IPO — but not for Covid

With the chief advisor for the Trump Administration's Covid-19 vaccine team as its chairman, vaccine developer Vaxcyte Inc. laid out plans for a $100 million IPO. But instead of targeting the coronavirus that has infected more than 5.5 million people worldwide and caused the disease that has killed nearly 350,000, Foster City-based Vaxcyte says it is instead focused on a vaccine against pneumonia. Vaxcyte, a seven-year-old spinoff of South San Francisco's Sutro Bipharma Inc. (NASDAQ: STRO), changed…